Mednet Logo
Community

How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alternative makes more sense?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on

In recent weeks, I have had several patients progressing on or immediately after stopping durvalumab following chemoradiation—a frustrating and difficult situation. In the patients I saw (without mixed histology), I discussed clinical trials of post-immune therapy progression. The particular questio...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Chicago Health Medical Group
Answered on

Car I/ etoposide/ atezo.

Join for free or sign in to see the full answer